Screening Libraries
| Cat. | Size | Price | Stock | |
| P20091 | 1mg/well * 20 Compounds | Inquiry | In stock | Contact Us |
| P20091 | 100uL/well (10mM solution) * 20 Compounds | Inquiry | In stock |
| manager@chemfaces.com | |
| Tel | (0086)-27-8423-7683 |
| Shelf Life | (0086)-27-84254680 |
| Manufacturer | Wuhan ChemFaces Biochemical Co., Ltd. |
| Container | 96 Well Format Sample |
| Storage | Protected from air and light, refrigerate or freeze(2-8 °) |
| Shelf Life | 24 months (2-8 °) |
| Intended Use | For research use only. Not for human use. Not sell to patients |
| 1. The products in the ChemFaces screening libraries are all from plants. |
| 2. The biological activities or pharmacological activities of all the ChemFaces products are derived from the databases of all over the world the latest literatures, you can according to the product manuals on our website to access the relevant literatures, hope that our informations can give some inspirations and help to your research. |
| 3.The collections of unique natural products, which include antioxidants, anti-inflammatory, antibacterial, anticancer, and ect. Can be used for high throughput screening (HTS) and high content screening (HCS), is to help you carry out new drug screening, the emergence of new indications and other professional tools. |
| 4.Structurally diverse, medicinally active, and cell permeable, NMR and HPLC validated to ensure high purity. |
| 5. ChemFaces offers customized bioactive screening libraries , whereby you choose the specific compounds you want in the library, the quantities, plate map, concentration, and format (dry/solid or DMSO solution). |
| Catalog No. | Information |
| CFN98612 | Cimifugin Cimifugin evidently inhibits FITC-induced type 2 allergic contact dermatitis,and its mechanism might related to regulating the balance of Th1 /Th2 by inhibiting type 2 cytokines. Cimifugin displayed low to moderate inhibition towards AChE and BChE (3.12 and 21.63%, respectively) at 200 ug/mL. |
| CFN98104 | Prim-O-glucosylcimifugin Prim-O-glucosylcimifugin is main medicinal component of the traditional Chinese drug Saposhnikovia divaricata, has inhibition on NO production and DPPH free radical, it can inhibit the proliferation of smooth muscle cell stimulated by TNF-α and increase the proportion of G0/G1 phase. |
| CFN97049 | Isoacteoside Isoacteoside exhibits significant inhibition of advanced glycation end product formation with IC50 values of 4.6-25.7 μM; it has neuroprotective, antioxidant, and anti-inflammatory effects. Isoacteoside can stimulate the increase of α7 and α3 proteins in the cultured cells, attenuate the decreased expression of α3 and α7 nAChR subunit proteins and cell viability on SH-SY5Y cells induced by Aβ; it can regulate caspase-1, mitogen-activated protein kinases (c-Jun N-terminal kinase, p38, extracellular signal-regulated protein kinase) and nuclear factor-kappa B pathways. |
| CFN97048 | Acteoside Acteoside is a lipase inhibitor, has neuroprotective, anti-obesity,anti-inflammatory, antioxidant, anticancer, cytotoxic,antihypertensive, analgesic, and antimetastatic activities. Acteoside can promote nerve growth factor and tropomycin receptor kinase A expression, inhibit arachidonic acid release and prostaglandin E2 production induced by 0.5 microM melittin. Acteoside can protect the cells from X‑ray induced damage through enhancing the scavenging activity of ROS, decreasing the Bax/Bcl-2 ratio and downregulating the activity of procaspase-3, as well as modulating the mitogen‑activated protein kinase signaling pathways. |
| CFN99864 | Actein Actein has a stimulatory effect on osteoblastic bone formation or has potential activity against osteoporosis, it also can prevent oxidative damage to osteoblasts in osteoporotic patients. Actein's ability to pathways involved in lipid disorders and carcinogenesis may make it a new agent for preventing and treating these major disorders, it has been shown to inhibit the proliferation of human breast cancer cells, by altering the activity of the ER IP3 receptor and Na,K-ATPase, inducing calcium release and modulating the NF-κB and MEK pathways. |
| CFN99465 | Cimidahurinine Cimidahurinine can attenuate Doxorubicin (DOX)-induced cardiotoxicity in a dose-dependent manner with EC50 values of 45.79 uM; it protects against cardiotoxicity by decreasing reactive oxygen species (ROS) accumulation and downregulating apoptosis-related Bax/Bcl-2 proteins. |
| CFN98679 | Norkhellol Reference standards. |
| CFN98340 | Cimigenoside |
| CFN98288 | Cimiracemoside C The Cimicifuga racemosa extract Ze 450 and some of its components (23-epi-26-deoxyactein, protopine and cimiracemoside C) can reduce significantly body weight, plasma glucose, improve glucose metabolism and insulin sensitivity in diabetic ob/ob mice; suggests that part of the effects may be related to AMPK activation.Ze 450 may have utility in the treatment of type 2 diabetes. |
| CFN98282 | Isoferulic acid Isoferulic acid is an effective natural antioxidant in both lipid and aqueous media, it may be a new promising anti-glycation agent for the prevention of diabetic complications via inhibition of advanced glycation end products (AGEs) formation and oxidation-dependent protein damage. Isoferulic acid is a novel and potent inhibitor of murine IL-8 production, it also has inhibitory effect on mushroom tyrosinase. |
